Briakinumab for treatment of Crohn's disease: results of a randomized trial.

<h4>Background</h4>This study assessed the efficacy and safety of briakinumab, a human anti-IL-12/23p40 monoclonal antibody, compared with placebo for the induction and maintenance of remission in patients with moderately to severely active Crohn's disease.<h4>Methods</h4>In this phase 2b, multicent... View More